Dr. Juliane Bernholz has over 25 years experience working in the pharmaceutical and biotech industry in a variety of senior R&D and business development roles. She joined AM-Pharma as Chief Operating Officer in October 2019 where she was responsible for Clinical, Regulatory & Quality and Manufacturing activities. Since September 2023 she assumed the role of CEO.
Prior to joining AM-Pharma Juliane was a Compound Development Team Leader at Janssen R&D LLC in New Jersey, US, leading projects in Cardiovascular and Infectious Diseases. Before her time at Janssen, Juliane held a number of international leadership roles in big Pharma and Biotech companies. These included Lead for International Partnering in the Diabetes Division at Sanofi where she successfully executed cell therapy and drug discovery collaboration deal. She also served as Senior Global Program Head of the Critical Care Franchise at Novartis Pharma, where she led work on its Rare Disease Cystic Fibrosis projects. Her prior career included a variety of senior roles at Actelion, Novartis, Ciba and Sandoz.
Juliane holds a PhD in Cell biology from the Biozentrum of the University of Basel, Switzerland and a Board Director Diploma from the International Institute for Management Development (IMD), Lausanne, Switzerland.